Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Abrams

Showing results (981-990 of 1,030) with videos related to

Pageof 103
Sort By:
Gastrointestinal Endoscopy|November 23, 2025
Durability of Cryoballoon Ablation for Eradication of Neoplastic Barrett's Esophagus: A Multicenter Prospective Cohort StudyMarcia Irene Canto, Arvind J Trindade, Amitabh Chak, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Gastrointestinal Endoscopy|January 19, 2020
Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort studyFouad Otaki, Gene K Ma, Anna Krigel, et al.
Annals of Surgery|February 22, 2024
Anatomic Lung Resection Outcomes After Implementation of a Universal Thoracic ERAS Protocol Across a Diverse Health Care SystemAdam R Dyas, Christina M Stuart, Michael R Bronsert, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibitionTheresa Baumeister, Andrea Proaño-Vasco, Amira Metwaly, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 17, 2015
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's EsophagusAndrew K Joe, Felice Schnoll-Sussman, Robert S Bresalier, et al.
Plos One|October 27, 2017
Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture studyXiangqing Sun, Apoorva K Chandar, Marcia I Canto, et al.
Nature|October 12, 2017
Transitional basal cells at the squamous-columnar junction generate Barrett's oesophagusMing Jiang, Haiyan Li, Yongchun Zhang, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases|June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialStanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Pageof 103

Showing results (981-990 of 1,030) with videos related to

Sort By:
Pageof 103
Gastrointestinal Endoscopy|November 23, 2025
Durability of Cryoballoon Ablation for Eradication of Neoplastic Barrett's Esophagus: A Multicenter Prospective Cohort StudyMarcia Irene Canto, Arvind J Trindade, Amitabh Chak, et al.
The Lancet. Oncology|November 26, 2009
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 studyAndrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, et al.
Gastrointestinal Endoscopy|January 19, 2020
Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort studyFouad Otaki, Gene K Ma, Anna Krigel, et al.
Annals of Surgery|February 22, 2024
Anatomic Lung Resection Outcomes After Implementation of a Universal Thoracic ERAS Protocol Across a Diverse Health Care SystemAdam R Dyas, Christina M Stuart, Michael R Bronsert, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibitionTheresa Baumeister, Andrea Proaño-Vasco, Amira Metwaly, et al.
Cancer Prevention Research (Philadelphia, Pa.)|October 17, 2015
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's EsophagusAndrew K Joe, Felice Schnoll-Sussman, Robert S Bresalier, et al.
Plos One|October 27, 2017
Genomic regions associated with susceptibility to Barrett's esophagus and esophageal adenocarcinoma in African Americans: The cross BETRNet admixture studyXiangqing Sun, Apoorva K Chandar, Marcia I Canto, et al.
Nature|October 12, 2017
Transitional basal cells at the squamous-columnar junction generate Barrett's oesophagusMing Jiang, Haiyan Li, Yongchun Zhang, et al.
Antiviral Therapy|June 28, 2013
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis CJean-Pierre Bronowicki, Stanislas Pol, Paul J Thuluvath, et al.
The Lancet. Infectious Diseases|June 21, 2012
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trialStanislas Pol, Reem H Ghalib, Vinod K Rustgi, et al.
Pageof 103